This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
by Zacks Equity Research
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
by Zacks Equity Research
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
by Zacks Equity Research
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
by Zacks Equity Research
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
by Kinjel Shah
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
by Zacks Equity Research
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.
The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney
by Zacks Equity Research
Pfizer, Coca-Cola and The Walt Disney are part of the Zacks top Analyst Blog.
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
by Sundeep Ganoria
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
by Zacks Equity Research
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential
by Nalak Das
Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
by Zacks Equity Research
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
by Zacks Equity Research
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
by Kinjel Shah
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
5 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS Health and Pfizer have been highlighted in this Screen of The Week article.
PFE vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.
Should Value Investors Buy Pfizer (PFE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen
by Zacks Equity Research
J&J, Eli Lilly, Pfizer, Merck, Amgen are included in this Analyst Blog.